Bipolar Disorder

NRx Pharmaceuticals secures FDA Fast Track designation for NRX-100, a preservation-free formulation of intravenous ketamine for suicidal ideation in depression.

Research reveals significant risks of neonatal complications linked to in utero valproic acid exposure, emphasizing the need for careful management during pregnancy.

Valproic acid poses significant risks during pregnancy, including congenital malformations and neurodevelopmental disorders, necessitating careful treatment planning.

BioXcel Therapeutics has submitted an pre-sNDA meeting package for Igalmi's outpatient use, aiming to enhance treatment options for agitation in bipolar disorders and schizophrenia.

Discover innovative strategies for early diagnosis and treatment of bipolar disorder, addressing challenges and exploring promising new therapies.

There is a critical link between sleep disorders and psychiatric conditions. In this Special Report, examine effective diagnosis and treatment strategies for better patient outcomes.

New research reveals the complex relationship between ADHD and bipolar disorder, highlighting genetic overlaps and treatment considerations for effective management.

Effective diagnosis and treatment of comorbid disorders in patients with bipolar enhance care and lead to more optimal mental health outcomes.

Combination therapy of TMS and ketamine could enhance brain perfusion and neuroplasticity.

Check out the pipeline updates from April!

The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for treatment-resistant major depressive disorder has now demonstrated promise for reducing depressive symptoms of bipolar I disorder in an open-label feasibility and safety trial.

Adherence, switching, and quality of life are top concerns in BDI, and schizophrenia.

Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

Although diagnostic criteria for a depressive episode are the same for unipolar major depression and bipolar depression, these episodes differ in their natural history.

Pipeline drug BHV-7000 failed to meet primary endpoint in a pivotal phase 2/3 trial for bipolar disorder; meanwhile, BHV-1300 sees success in sustained Reductions in Total IgG.

How should clinicians approach treatment when their patient disagrees with the diagnosis?

The FDA has accepted the supplemental New Drug Application for Uzedy extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults.

Learn more about the latest research on bipolar disorder, including the impacts of childhood trauma on its development and the correlation between bipolar disorder and cardiovascular risk.

Bipolar disorder is both underdiagnosed and overdiagnosed—though missing the diagnosis is more common. Check out this update from David N. Osser, MD.

Researchers identified 298 genetic regions linked to bipolar disorder risk in the largest study of its kind.

Bipolar I disorder (BD-I) can be difficult to diagnose and treat due to overlapping symptoms and stigma. What can clinicians utilize to help manage BD-I for better long-term outcomes?

In this CME article, learn more about recent developments with lithium as they relate to renal issues.

Looking to buy books as gifts this year? We've got you covered.

Let’s compare treatment risks when managing mixed states.

Can "healing" life trauma help improve bipolar disorder symptoms?

Here are 4 means of coping with the diagnostic uncertainty of bipolar mixed states.

How can you distinguish bipolar mixed states? Stay tuned in this short series.

Learn more about a specific subset of mood disorders.

A refined rTMS protocol, the Stanford Accelerated Intelligent Neuromodulation Therapy for major depressive disorder, shows promise in bipolar disorder.

“Older medications” like ECT, lithium, second generation antipsychotics such as the olanzapine/fluoxetine combination, have proven efficacy.